Pembrolizumab plus tumor ablation for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests combining an immunotherapy drug (pembrolizumab, also called Keytruda) with a procedure that freezes or destroys cancer cells directly (called ablation). The goal is to see if this combination can help control triple-negative breast cancer that has spread or is inoperable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have triple-negative breast cancer that has spread (metastatic) or is inoperable (too large or in a difficult spot for surgery).
- You have at least one tumor that is at least 1.5 cm in size (about the size of a grape) that can be safely destroyed using a freezing or sound-wave procedure.
- Your doctor is already planning to treat you with pembrolizumab (Keytruda) as part of your standard care.
- If you are of childbearing age, you must be willing to use effective birth control during treatment and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.